A Trial to Assess the Efficacy and Safety of OTR4132-MD in Patients With Acute Ischemic Stroke
NCT: NCT06700824 · COMPLETED
Brief Summary
The MaTRISS 2 study is a phase 2 randomized, double-blinded and placebo-controlled trial aimed at recruiting 60 subjects (30 placebo and 30 active) from 15 stroke centers in France. The main objective will be to assess the efficacy of OTR4132-MD in patients with anterior ischemic stroke after endovascular thrombectomy. One dose will be tested (2 mg) against placebo. The main outcomes will be NIHSS (neurological score) at 24 hours, rate of intracranial hemorrhages at 24 hours, MRI lesion volume at 3 months and neurological scores at 3 months.
Frequently Asked Questions
What is A Trial to Assess the Efficacy and Safety of OTR4132-MD in Patients With Acute Ischemic Stroke?
A Trial to Assess the Efficacy and Safety of OTR4132-MD in Patients With Acute Ischemic Stroke is a clinical trial registered under NCT06700824. Current status: COMPLETED.
What is the status of NCT06700824?
The current status of NCT06700824 (A Trial to Assess the Efficacy and Safety of OTR4132-MD in Patients With Acute Ischemic Stroke) is: COMPLETED.
When did A Trial to Assess the Efficacy and Safety of OTR4132-MD in Patients With Acute Ischemic Stroke start?
A Trial to Assess the Efficacy and Safety of OTR4132-MD in Patients With Acute Ischemic Stroke started on 2025-03-14.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.